Psoriasis: Which therapy for which patient

Psoriasis comorbidities and preferred systemic agents
      Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities, such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular diseases. These factors have a significant impact on the decision to use one therapy over another. The past decade has seen a paradigm shift in our understanding of the pathogenesis of psoriasis that has led to identification of new therapeutic targets. Several new drugs have gained approval by the US Food and Drug Administration, expanding the psoriasis armamentarium, but still a large number of patients continue to be untreated or undertreated. Treatment regimens for psoriasis patients should be tailored to meet the specific needs based on disease severity, the impact on quality of life, the response to previous therapies, and the presence of comorbidities. The first article in this continuing medical education series focuses on specific comorbidities and provides insights to choose appropriate systemic treatment in patients with moderate to severe psoriasis.

      Keywords

      Abbreviations used:

      ATIL (anti–tumor necrosis factor-α–induced lupus), CD (Crohn's disease), CHF (congestive heart failure), DLE (discoid lupus erythematosus), IBD (inflammatory bowel disease), LE (lupus erythematosus), MACE (major adverse cardiovascular event), MI (myocardial infarction), MS (multiple sclerosis), NMSC (nonmelanoma skin cancer), NYHA (New York Heart Association), OLE (open label extension), PASI (Psoriasis Area Severity Index), RCT (randomized controlled trial), SCC (squamous cell carcinoma), SCLE (subacute cutaneous lupus erythematosus), UC (ulcerative colitis)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Takeshita J.
        • Grewal S.
        • Langan S.M.
        • et al.
        Psoriasis and comorbid diseases: epidemiology.
        J Am Acad Dermatol. 2017; 76: 377-390
        • Lebwohl M.G.
        • Bachelez H.
        • Barker J.
        • et al.
        Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.
        J Am Acad Dermatol. 2014; 70 (e1-30): 871-881
        • Villani A.P.
        • Rouzaud M.
        • Sevrain M.
        • et al.
        Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis.
        J Am Acad Dermatol. 2015; 73: 242-248
        • Dominguez-Rosado I.
        • Moutinho Jr., V.
        • DeMatteo R.P.
        • Kingham T.P.
        • D'Angelica M.
        • Brennan M.F.
        Outcomes of the Memorial Sloan Kettering Cancer Center International General Surgical Oncology Fellowship.
        J Am Coll Surg. 2016; 222: 961-966
        • Gladman D.D.
        • Stafford-Brady F.
        • Chang C.H.
        • Lewandowski K.
        • Russell M.L.
        Longitudinal study of clinical and radiological progression in psoriatic arthritis.
        J Rheumatol. 1990; 17: 809-812
        • McHugh N.J.
        • Balachrishnan C.
        • Jones S.M.
        Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study.
        Rheumatology (Oxford). 2003; 42: 778-783
        • Ash Z.
        • Gaujoux-Viala C.
        • Gossec L.
        • et al.
        A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.
        Ann Rheum Dis. 2012; 71: 319-326
        • Kingsley G.H.
        • Kowalczyk A.
        • Taylor H.
        • et al.
        A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.
        Rheumatology (Oxford). 2012; 51: 1368-1377
        • Pincus T.
        • Bergman M.J.
        • Yazici Y.
        Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?.
        Clin Exp Rheumatol. 2015; 33: S82-S93
        • Mease P.J.
        • Goffe B.S.
        • Metz J.
        • VanderStoep A.
        • Finck B.
        • Burge D.J.
        Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
        Lancet. 2000; 356: 385-390
        • Gupta A.K.
        • Matteson E.L.
        • Ellis C.N.
        • et al.
        Cyclosporine in the treatment of psoriatic arthritis.
        Arch Dermatol. 1989; 125: 507-510
        • Steinsson K.
        • Jonsdottir I.
        • Valdimarsson H.
        Cyclosporin A in psoriatic arthritis: an open study.
        Ann Rheum Dis. 1990; 49: 603-606
        • Salvarani C.
        • Macchioni P.
        • Boiardi L.
        • et al.
        Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy.
        J Rheumatol. 1992; 19: 74-79
        • Mahrle G.
        • Schulze H.J.
        • Brautigam M.
        • et al.
        Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study.
        Br J Dermatol. 1996; 135: 752-757
        • Fraser A.D.
        • van Kuijk A.W.
        • Westhovens R.
        • et al.
        A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
        Ann Rheum Dis. 2005; 64: 859-864
        • D'Angelo S.
        • Cutro M.S.
        • Lubrano E.
        • et al.
        Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis.
        Ann Rheum Dis. 2010; 69: 934-935
        • Gladman D.D.
        • Thavaneswaran A.
        • Chandran V.
        • Cook R.J.
        Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?.
        Ann Rheum Dis. 2011; 70: 2152-2154
        • Kirkham B.
        • de Vlam K.
        • Li W.
        • et al.
        Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.
        Clin Exp Rheumatol. 2015; 33: 11-19
        • Mease P.J.
        • Gladman D.D.
        • Ritchlin C.T.
        • et al.
        Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
        Arthritis Rheum. 2005; 52: 3279-3289
        • Kavanaugh A.
        • McInnes I.
        • Mease P.
        • et al.
        Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
        Arthritis Rheum. 2009; 60: 976-986
        • Mease P.J.
        • Fleischmann R.
        • Deodhar A.A.
        • et al.
        Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
        Ann Rheum Dis. 2014; 73: 48-55
        • Ritchlin C.
        • Rahman P.
        • Kavanaugh A.
        • et al.
        Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
        Ann Rheum Dis. 2014; 73: 990-999
        • Jones B.B.
        • Millsop J.W.
        • Walsh J.A.
        • Krueger G.G.
        • Callis Duffin K.
        Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients.
        Br J Dermatol. 2015; 173: 272-274
        • Kavanaugh A.
        • Krueger G.G.
        • Beutler A.
        • et al.
        Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
        Ann Rheum Dis. 2007; 66: 498-505
        • Mease P.J.
        • Ory P.
        • Sharp J.T.
        • et al.
        Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
        Ann Rheum Dis. 2009; 68: 702-709
        • Bonifati C.
        • Graceffa D.
        How effective is ustekinumab in controlling psoriatic arthritis?.
        Dermatol Ther. 2016; 29: 155-159
        • McInnes I.B.
        • Sieper J.
        • Braun J.
        • et al.
        Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
        Ann Rheum Dis. 2014; 73: 349-356
        • Mease P.J.
        • McInnes I.B.
        • Kirkham B.
        • et al.
        Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis.
        N Engl J Med. 2015; 373: 1329-1339
        • McInnes I.B.
        • Mease P.J.
        • Kirkham B.
        • et al.
        Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2015; 386: 1137-1146
        • Nash P.
        • Kirkham B.
        • Okada M.
        • et al.
        Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
        Lancet. 2017; 389: 2317-2327
        • Mease P.J.
        • van der Heijde D.
        • Ritchlin C.T.
        • et al.
        Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
        Ann Rheum Dis. 2017; 76: 79-87
        • Mease P.J.
        • Genovese M.C.
        • Greenwald M.W.
        • et al.
        Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
        N Engl J Med. 2014; 370: 2295-2306
        • Kavanaugh A.
        • Mease P.J.
        • Gomez-Reino J.J.
        • et al.
        Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
        Ann Rheum Dis. 2014; 73: 1020-1026
        • Cutolo M.
        • Myerson G.E.
        • Fleischmann R.M.
        • et al.
        A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial.
        J Rheumatol. 2016; 43: 1724-1734
        • Edwards C.J.
        • Blanco F.J.
        • Crowley J.
        • et al.
        Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
        Ann Rheum Dis. 2016; 75: 1065-1073
        • Pathan E.
        • Abraham S.
        • Van Rossen E.
        • et al.
        Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
        Ann Rheum Dis. 2013; 72: 1475-1480
        • Mease P.
        • Genovese M.C.
        • Gladstein G.
        • et al.
        Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
        Arthritis Rheum. 2011; 63: 939-948
        • Di Cesare A.
        • Di Meglio P.
        • Nestle F.O.
        The IL-23/Th17 axis in the immunopathogenesis of psoriasis.
        J Invest Dermatol. 2009; 129: 1339-1350
        • Rovedatti L.
        • Kudo T.
        • Biancheri P.
        • et al.
        Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease.
        Gut. 2009; 58: 1629-1636
        • Abraham C.
        • Cho J.H.
        Inflammatory bowel disease.
        N Engl J Med. 2009; 361: 2066-2078
        • Cohen A.D.
        • Dreiher J.
        • Birkenfeld S.
        Psoriasis associated with ulcerative colitis and Crohn's disease.
        J Eur Acad Dermatol Venereol. 2009; 23: 561-565
        • Li W.Q.
        • Han J.L.
        • Chan A.T.
        • Qureshi A.A.
        Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women.
        Ann Rheum Dis. 2013; 72: 1200-1205
        • Tsai T.F.
        • Wang T.S.
        • Hung S.T.
        • et al.
        Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan.
        J Dermatol Sci. 2011; 63: 40-46
        • Edson-Heredia E.
        • Zhu B.
        • Lefevre C.
        • et al.
        Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink.
        J Eur Acad Dermatol Venereol. 2015; 29: 955-963
        • Wu J.J.
        • Nguyen T.U.
        • Poon K.Y.
        • Herrinton L.J.
        The association of psoriasis with autoimmune diseases.
        J Am Acad Dermatol. 2012; 67: 924-930
        • Augustin M.
        • Reich K.
        • Glaeske G.
        • Schaefer I.
        • Radtke M.
        Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany.
        Acta Derm Venereol. 2010; 90: 147-151
        • McDonald J.W.
        • Tsoulis D.J.
        • Macdonald J.K.
        • Feagan B.G.
        Methotrexate for induction of remission in refractory Crohn's disease.
        Cochrane Database Syst Rev. 2012; 12: CD003459
        • Feagan B.G.
        • McDonald J.W.
        • Rochon J.
        • et al.
        Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
        N Engl J Med. 1994; 330: 1846-1851
        • Stange E.F.
        • Modigliani R.
        • Pena A.S.
        • Wood A.J.
        • Feutren G.
        • Smith P.R.
        European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group.
        Gastroenterology. 1995; 109: 774-782
        • Lee S.Y.
        • Jamal M.M.
        • Nguyen E.T.
        • Bechtold M.L.
        • Nguyen D.L.
        Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis.
        Eur J Gastroenterol Hepatol. 2016; 28: 210-216
        • Tenner S.
        Isotretinoin and inflammatory bowel disease: trial lawyer misuse of science and FDA warnings.
        Am J Gastroenterol. 2014; 109: 570-571
      1. Isotretinoin, acne, and Crohn's disease: a convergence of bad skin, bad science, and bad litigation creates the perfect storm.
        Gastroenterol Hepatol (N Y). 2013; 9: 752-755
        • Hanauer S.B.
        • Feagan B.G.
        • Lichtenstein G.R.
        • et al.
        Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
        Lancet. 2002; 359: 1541-1549
        • Sands B.E.
        • Anderson F.H.
        • Bernstein C.N.
        • et al.
        Infliximab maintenance therapy for fistulizing Crohn's disease.
        N Engl J Med. 2004; 350: 876-885
        • Hanauer S.B.
        • Sandborn W.J.
        • Rutgeerts P.
        • et al.
        Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
        Gastroenterology. 2006; 130: 323-333
        • Sandborn W.J.
        • Lee S.D.
        • Randall C.
        • et al.
        Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.
        Aliment Pharmacol Ther. 2014; 40: 903-916
        • Sandborn W.J.
        • Schreiber S.
        • Hanauer S.B.
        • Colombel J.F.
        • Bloomfield R.
        • Lichtenstein G.R.
        Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
        Clin Gastroenterol Hepatol. 2010; 8: 696-702.e1
        • Osterman M.T.
        • Haynes K.
        • Delzell E.
        • et al.
        Comparative effectiveness of infliximab and adalimumab for Crohn's disease.
        Clin Gastroenterol Hepatol. 2014; 12: 811-817.e3
        • Kestens C.
        • van Oijen M.G.
        • Mulder C.L.
        • et al.
        Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents.
        Clin Gastroenterol Hepatol. 2013; 11: 826-831
        • Sandborn W.J.
        • Feagan B.G.
        • Marano C.
        • et al.
        Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
        Gastroenterology. 2014; 146: 85-95
        • Feagan B.G.
        • Sandborn W.J.
        • Gasink C.
        • et al.
        Ustekinumab as induction and maintenance therapy for Crohn's disease.
        N Engl J Med. 2016; 375: 1946-1960
        • van de Kerkhof P.C.
        • Griffiths C.E.
        • Reich K.
        • et al.
        Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
        J Am Acad Dermatol. 2016; 75: 83-98.e4
        • Hueber W.
        • Sands B.E.
        • Lewitzky S.
        • et al.
        Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
        Gut. 2012; 61: 1693-1700
        • Gordon K.B.
        • Blauvelt A.
        • Papp K.A.
        • et al.
        Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis.
        N Engl J Med. 2016; 375: 345-356
        • Reich K.
        • Leonardi C.
        • Langley R.G.
        • et al.
        Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
        J Am Acad Dermatol. 2017; 76: 441-448.e2
        • Papp K.A.
        • Leonardi C.
        • Menter A.
        • et al.
        Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
        N Engl J Med. 2012; 366: 1181-1189
        • Lebwohl M.
        • Strober B.
        • Menter A.
        • et al.
        Phase 3 studies comparing brodalumab with ustekinumab in psoriasis.
        N Engl J Med. 2015; 373: 1318-1328
        • Feagan B.G.
        • Sandborn W.J.
        • D'Haens G.
        • et al.
        Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
        Lancet. 2017; 389: 1699-1709
        • Izzo A.A.
        • Mascolo N.
        • Capasso F.
        Effect of selective phosphodiesterase inhibitors on synaptic transmission in the guinea-pig ileum.
        Naunyn Schmiedebergs Arch Pharmacol. 1998; 357: 677-681
        • Salari-Sharif P.
        • Abdollahi M.
        Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.
        Curr Pharm Des. 2010; 16: 3661-3667
        • Nyfors A.
        • Jensen H.
        Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study.
        Dermatologica. 1983; 167: 260-261
        • Ebeo C.T.
        • Girish M.R.
        • Byrd R.P.
        • Roy T.M.
        • Mehta J.B.
        Methotrexate-induced pulmonary lymphoma.
        Chest. 2003; 123: 2150-2153
        • Paul C.
        • Le Tourneau A.
        • Cayuela J.M.
        • et al.
        Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis.
        Arch Dermatol. 1997; 133: 867-871
        • Khopkar U.
        • Bhor U.
        Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy.
        Indian J Dermatol Venereol Leprol. 2008; 74: 379-382
        • Patel R.V.
        • Clark L.N.
        • Lebwohl M.
        • Weinberg J.M.
        Treatments for psoriasis and the risk of malignancy.
        J Am Acad Dermatol. 2009; 60: 1001-1017
        • Paul C.F.
        • Ho V.C.
        • McGeown C.
        • et al.
        Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
        J Invest Dermatol. 2003; 120: 211-216
        • Bavinck J.N.
        • Tieben L.M.
        • Van der Woude F.J.
        • et al.
        Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study.
        J Clin Oncol. 1995; 13: 1933-1938
        • McKenna D.B.
        • Murphy G.M.
        Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin.
        Br J Dermatol. 1999; 140: 656-660
        • de Sevaux R.G.
        • Smit J.V.
        • de Jong E.M.
        • van de Kerkhof P.C.
        • Hoitsma A.J.
        Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin.
        J Am Acad Dermatol. 2003; 49: 407-412
        • Bongartz T.
        • Sutton A.J.
        • Sweeting M.J.
        • Buchan I.
        • Matteson E.L.
        • Montori V.
        Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
        JAMA. 2006; 295: 2275-2285
        • Asgari M.M.
        • Ray G.T.
        • Geier J.L.
        • Quesenberry C.P.
        Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
        J Am Acad Dermatol. 2017; 76: 632-638
        • Nannini C.
        • Cantini F.
        • Niccoli L.
        • et al.
        Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures?.
        Arthritis Rheum. 2009; 61: 801-812
        • Wolfe F.
        • Michaud K.
        Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.
        Arthritis Rheum. 2007; 56: 2886-2895
        • Brewer J.D.
        • Hoverson Schott A.R.
        • Roenigk R.K.
        Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature.
        Int J Dermatol. 2011; 50: 1555-1559
        • Fryrear 2nd, R.S.
        • Wiggins A.K.
        • Sangueza O.
        • Yosipovitch G.
        Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy.
        J Am Acad Dermatol. 2004; 51: 1026
        • Ly L.
        • Czarnecki D.
        The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis.
        Br J Dermatol. 2007; 157: 1076-1078
        • Smith K.J.
        • Skelton H.G.
        Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy.
        J Am Acad Dermatol. 2001; 45: 953-956
        • Burge D.
        Etanercept and squamous cell carcinoma.
        J Am Acad Dermatol. 2003; 49: 358-359
        • Askling J.
        • Fahrbach K.
        • Nordstrom B.
        • Ross S.
        • Schmid C.H.
        • Symmons D.
        Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
        Pharmacoepidemiol Drug Saf. 2011; 20: 119-130
        • Mariette X.
        • Matucci-Cerinic M.
        • Pavelka K.
        • et al.
        Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.
        Ann Rheum Dis. 2011; 70: 1895-1904
        • Raaschou P.
        • Simard J.F.
        • Holmqvist M.
        • Askling J.
        Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.
        BMJ. 2013; 346: f1939
        • Girard C.
        • Guillot B.
        • Bessis D.
        Gastric MALT lymphoma in a patient receiving infliximab for psoriasis.
        Br J Dermatol. 2008; 159: 497-498
        • Bonovas S.
        • Minozzi S.
        • Lytras T.
        • et al.
        Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
        Expert Opin Drug Saf. 2016; 15: 35-54
        • Ustekinumab
        new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
        Prescrire Int. 2009; 18: 202-204
        • Gordon K.B.
        • Papp K.A.
        • Langley R.G.
        • et al.
        Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
        J Am Acad Dermatol. 2012; 66: 742-751
        • Papp K.A.
        • Griffiths C.E.
        • Gordon K.
        • et al.
        Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
        Br J Dermatol. 2013; 168: 844-854
        • Fiorentino D.
        • Ho V.
        • Lebwohl M.G.
        • et al.
        Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
        J Am Acad Dermatol. 2017; 77: 845-854.e5
        • Salopek T.G.
        Recurrence of melanoma after starting apremilast for psoriasis.
        Case Rep Dermatol. 2017; 9: 108-111
        • Gisondi P.
        • Galvan A.
        • Idolazzi L.
        • Girolomoni G.
        Management of moderate to severe psoriasis in patients with metabolic comorbidities.
        Front Med (Lausanne). 2015; 2: 1
        • Armstrong A.W.
        • Harskamp C.T.
        • Armstrong E.J.
        The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies.
        Nutr Diabetes. 2012; 2: e54
        • Fleming P.
        • Kraft J.
        • Gulliver W.P.
        • Lynde C.
        The relationship of obesity with the severity of psoriasis: a systematic review.
        J Cutan Med Surg. 2015; 19: 450-456
        • Gisondi P.
        • Targher G.
        • Zoppini G.
        • Girolomoni G.
        Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
        J Hepatol. 2009; 51: 758-764
        • Gisondi P.
        • Barba E.
        • Girolomoni G.
        Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis.
        J Eur Acad Dermatol Venereol. 2016; 30: 282-287
        • Rosenberg P.
        • Urwitz H.
        • Johannesson A.
        • et al.
        Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment.
        J Hepatol. 2007; 46: 1111-1118
        • Nast A.
        • Gisondi P.
        • Ormerod A.D.
        • et al.
        European S3-guidelines on the systemic treatment of psoriasis vulgaris–update 2015–short version–EDF in cooperation with EADV and IPC.
        J Eur Acad Dermatol Venereol. 2015; 29: 2277-2294
        • Powles A.V.
        • Hardman C.M.
        • Porter W.M.
        • Cook T.
        • Hulme B.
        • Fry L.
        Renal function after 10 years' treatment with cyclosporin for psoriasis.
        Br J Dermatol. 1998; 138: 443-449
        • Lowe N.J.
        • Wieder J.M.
        • Rosenbach A.
        • et al.
        Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure.
        J Am Acad Dermatol. 1996; 35: 710-719
        • Gisondi P.
        • Cazzaniga S.
        • Chimenti S.
        • et al.
        Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.
        J Eur Acad Dermatol Venereol. 2013; 27: e30-e41
        • Gordon K.
        • Korman N.
        • Frankel E.
        • et al.
        Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
        J Am Acad Dermatol. 2006; 54: S101-S111
        • Menter A.
        • Gordon K.B.
        • Leonardi C.L.
        • Gu Y.
        • Goldblum O.M.
        Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
        J Am Acad Dermatol. 2010; 63: 448-456
        • Saurat J.H.
        • Stingl G.
        • Dubertret L.
        • et al.
        Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
        Br J Dermatol. 2008; 158: 558-566
        • Prussick R.
        • Unnebrink K.
        • Valdecantos W.C.
        Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis.
        J Drugs Dermatol. 2015; 14: 864-868
        • Iannone F.
        • Lopalco G.
        • Rigante D.
        • Orlando I.
        • Cantarini L.
        • Lapadula G.
        Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy.
        Autoimmun Rev. 2016; 15: 447-450
        • Zhu Y.
        • Hu C.
        • Lu M.
        • et al.
        Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.
        J Clin Pharmacol. 2009; 49: 162-175
        • Papp K.A.
        • Langley R.G.
        • Sigurgeirsson B.
        • et al.
        Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
        Br J Dermatol. 2013; 168: 412-421
        • Reich K.
        • Puig L.
        • Mallbris L.
        • Zhang L.
        • Osuntokun O.
        • Leonardi C.
        The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis.
        J Eur Acad Dermatol Venereol. 2017; 31: 1196-1207
        • Papp K.A.
        • Reich K.
        • Paul C.
        • et al.
        A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
        Br J Dermatol. 2016; 175: 273-286
        • Paul C.
        • Cather J.
        • Gooderham M.
        • et al.
        Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
        Br J Dermatol. 2015; 173: 1387-1399
        • Vujic I.
        • Herman R.
        • Sanlorenzo M.
        • et al.
        Apremilast in psoriasis - a prospective real-world study.
        J Eur Acad Dermatol Venereol. 2018; 32: 254-259
        • Gelfand J.M.
        • Neimann A.L.
        • Shin D.B.
        • Wang X.
        • Margolis D.J.
        • Troxel A.B.
        Risk of myocardial infarction in patients with psoriasis.
        JAMA. 2006; 296: 1735-1741
        • Gisondi P.
        • Girolomoni G.
        Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
        Semin Thromb Hemost. 2009; 35: 313-324
        • Rocha-Pereira P.
        • Santos-Silva A.
        • Rebelo I.
        • Figueiredo A.
        • Quintanilha A.
        • Teixeira F.
        The inflammatory response in mild and in severe psoriasis.
        Br J Dermatol. 2004; 150: 917-928
        • Vanizor Kural B.
        • Orem A.
        • Cimsit G.
        • Uydu H.A.
        • Yandi Y.E.
        • Alver A.
        Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients.
        Clin Chim Acta. 2003; 332: 23-30
        • Hansson G.K.
        Inflammation, atherosclerosis, and coronary artery disease.
        N Engl J Med. 2005; 352: 1685-1695
        • Prodanovich S.
        • Ma F.
        • Taylor J.R.
        • Pezon C.
        • Fasihi T.
        • Kirsner R.S.
        Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
        J Am Acad Dermatol. 2005; 52: 262-267
        • Dunn L.K.
        • Gaar L.R.
        • Yentzer B.A.
        • O'Neill J.L.
        • Feldman S.R.
        Acitretin in dermatology: a review.
        J Drugs Dermatol. 2011; 10: 772-782
        • Stern R.S.
        • Fitzgerald E.
        • Ellis C.N.
        • Lowe N.
        • Goldfarb M.T.
        • Baughman R.D.
        The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study.
        J Am Acad Dermatol. 1995; 33: 44-52
        • Rezzani R.
        Exploring cyclosporine A-side effects and the protective role-played by antioxidants: the morphological and immunohistochemical studies.
        Histol Histopathol. 2006; 21: 301-316
        • Robert N.
        • Wong G.W.
        • Wright J.M.
        Effect of cyclosporine on blood pressure.
        Cochrane Database Syst Rev. 2010; 1: CD007893
        • Ahlehoff O.
        • Skov L.
        • Gislason G.
        • et al.
        Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.
        J Intern Med. 2013; 273: 197-204
        • Wu J.J.
        • Poon K.Y.
        Association of gender, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis.
        J Am Acad Dermatol. 2013; 69: 650-651
        • Abuabara K.
        • Lee H.
        • Kimball A.B.
        The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study.
        Br J Dermatol. 2011; 165: 1066-1073
        • Ryan C.
        • Leonardi C.L.
        • Krueger J.G.
        • et al.
        Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
        JAMA. 2011; 306: 864-871
        • Armstrong E.J.
        • Harskamp C.T.
        • Armstrong A.W.
        Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies.
        J Am Heart Assoc. 2013; 2: e000062
        • Gulliver W.P.
        • Young H.M.
        • Bachelez H.
        • Randell S.
        • Gulliver S.
        • Al-Mutairi N.
        Psoriasis patients treated with biologics and methotrexate have a reduced rate of myocardial infarction: a collaborative analysis using international cohorts.
        J Cutan Med Surg. 2016; 20: 550-554
        • Bissonnette R.
        • Tardif J.C.
        • Harel F.
        • Pressacco J.
        • Bolduc C.
        • Guertin M.C.
        Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial.
        Circ Cardiovasc Imaging. 2013; 6: 83-90
        • Bissonnette R.
        • Harel F.
        • Krueger J.G.
        • et al.
        TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study.
        J Invest Dermatol. 2017; 137: 1638-1645
        • Papp K.
        • Gottlieb A.B.
        • Naldi L.
        • et al.
        Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
        J Drugs Dermatol. 2015; 14: 706-714
        • Khalid U.
        • Ahlehoff O.
        • Gislason G.H.
        • et al.
        Psoriasis and risk of heart failure: a nationwide cohort study.
        Eur J Heart Fail. 2014; 16: 743-748
        • Yang Y.W.
        • Keller J.J.
        • Lin H.C.
        Medical comorbidity associated with psoriasis in adults: a population-based study.
        Br J Dermatol. 2011; 165: 1037-1043
        • Gong K.
        • Zhang Z.
        • Sun X.
        • et al.
        The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure.
        Am Heart J. 2006; 151: 62-68
        • Eisen H.J.
        Immunosuppression on the horizon.
        Heart Fail Clin. 2007; 3: 43-49
        • Yerly P.
        • Mach F.
        • Kalangos A.
        • et al.
        Monitoring and adjustment of immunosuppression after heart transplantation [in French].
        Rev Med Suisse. 2009; 5 (1214-1216, 1218-1220)
        • Groetzner J.
        • Reichart B.
        • Roemer U.
        • et al.
        Cardiac transplantation in pediatric patients: fifteen-year experience of a single center.
        Ann Thorac Surg. 2005; 79: 53-60
        • Tarone G.
        • Balligand J.L.
        • Bauersachs J.
        • et al.
        Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology.
        Eur J Heart Fail. 2014; 16: 494-508
        • Kwon H.J.
        • Cote T.R.
        • Cuffe M.S.
        • Kramer J.M.
        • Braun M.M.
        Case reports of heart failure after therapy with a tumor necrosis factor antagonist.
        Ann Intern Med. 2003; 138: 807-811
        • Kleinbongard P.
        • Schulz R.
        • Heusch G.
        TNFalpha in myocardial ischemia/reperfusion, remodeling and heart failure.
        Heart Fail Rev. 2011; 16: 49-69
        • Bozkurt B.
        • Torre-Amione G.
        • Warren M.S.
        • et al.
        Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure.
        Circulation. 2001; 103: 1044-1047
        • Desai S.B.
        • Furst D.E.
        Problems encountered during anti-tumour necrosis factor therapy.
        Best Pract Res Clin Rheumatol. 2006; 20: 757-790
        • Menter A.
        • Gottlieb A.
        • Feldman S.R.
        • et al.
        Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
        J Am Acad Dermatol. 2008; 58: 826-850
        • Langer-Gould A.
        • Albers K.B.
        • Van Den Eeden S.K.
        • Nelson L.M.
        Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study.
        Mult Scler. 2010; 16: 855-861
        • Egeberg A.
        • Mallbris L.
        • Gislason G.H.
        • Skov L.
        • Hansen P.R.
        Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study.
        J Invest Dermatol. 2016; 136: 93-98
        • Guido N.
        • Cices A.
        • Ibler E.
        • et al.
        Multiple sclerosis association with psoriasis: a large U.S. population, single centre, retrospective cross-sectional study.
        J Eur Acad Dermatol Venereol. 2017; 31: e397-e398
        • Edwards L.J.
        • Constantinescu C.S.
        A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic.
        Mult Scler. 2004; 10: 575-581
        • Ramagopalan S.V.
        • Dyment D.A.
        • Valdar W.
        • et al.
        Autoimmune disease in families with multiple sclerosis: a population-based study.
        Lancet Neurol. 2007; 6: 604-610
        • Neumann J.W.
        • Ziegler D.K.
        Therapeutic trial of immunosuppressive agents in multiple sclerosis.
        Neurology. 1972; 22: 1268-1271
        • Currier R.D.
        • Haerer A.F.
        • Meydrech E.F.
        Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.
        J Neurol Neurosurg Psychiatry. 1993; 56: 1217-1218
        • Ashtari F.
        • Savoj M.R.
        Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to interferon beta-1alpha: a randomized controlled trial.
        J Res Med Sci. 2011; 16: 457-462
        • Goodkin D.E.
        • Rudick R.A.
        • VanderBrug Medendorp S.
        • et al.
        Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.
        Ann Neurol. 1995; 37: 30-40
        • Zhao G.J.
        • Li D.K.
        • Wolinsky J.S.
        • et al.
        Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group.
        J Neuroimaging. 1997; 7: 1-7
        • Paty D.W.
        • Li D.K.
        Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article].
        Neurology. 2001; 57: S10-S15
        • Tristano A.G.
        Neurological adverse events associated with anti-tumor necrosis factor alpha treatment.
        J Neurol. 2010; 257: 1421-1431
        • Mohan N.
        • Edwards E.T.
        • Cupps T.R.
        • et al.
        Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.
        Arthritis Rheum. 2001; 44: 2862-2869
        • Cruz Fernandez-Espartero M.
        • Perez-Zafrilla B.
        • Naranjo A.
        • et al.
        Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
        Semin Arthritis Rheum. 2011; 41: 524-533
        • Ramos-Casals M.
        • Roberto Perez A.
        • Diaz-Lagares C.
        • Cuadrado M.J.
        • Khamashta M.A.
        Autoimmune diseases induced by biological agents: a double-edged sword?.
        Autoimmun Rev. 2010; 9: 188-193
        • Kay J.
        • Fleischmann R.
        • Keystone E.
        • et al.
        Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
        Ann Rheum Dis. 2015; 74: 538-546
        • Gomez-Gallego M.
        • Meca-Lallana J.
        • Fernandez-Barreiro A.
        Multiple sclerosis onset during etanercept treatment.
        Eur Neurol. 2008; 59: 91-93
        • Caminero A.
        • Comabella M.
        • Montalban X.
        Tumor necrosis factor alpha (TNF-alpha), anti-TNF-alpha and demyelination revisited: an ongoing story.
        J Neuroimmunol. 2011; 234: 1-6
        • Segal B.M.
        • Constantinescu C.S.
        • Raychaudhuri A.
        • Kim L.
        • Fidelus-Gort R.
        • Kasper L.H.
        Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
        Lancet Neurol. 2008; 7: 796-804
        • Havrdova E.
        • Belova A.
        • Goloborodko A.
        • et al.
        Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
        J Neurol. 2016; 263: 1287-1295
        • Zalla M.J.
        • Muller S.A.
        The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders.
        Acta Derm Venereol Suppl (Stockh). 1996; 195: 1-15
        • Carneiro J.R.
        • Sato E.I.
        Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.
        J Rheumatol. 1999; 26: 1275-1279
        • Al-Mutairi N.
        • Rijhwani M.
        • Nour-Eldin O.
        Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy.
        J Dermatol. 2005; 32: 482-486
        • Fortin P.R.
        • Abrahamowicz M.
        • Ferland D.
        • Lacaille D.
        • Smith C.D.
        • Zummer M.
        Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
        Arthritis Rheum. 2008; 59: 1796-1804
        • Rothenberg R.J.
        • Graziano F.M.
        • Grandone J.T.
        • Goldberg J.W.
        • Bjarnason D.F.
        • Finesilver A.G.
        The use of methotrexate in steroid-resistant systemic lupus erythematosus.
        Arthritis Rheum. 1988; 31: 612-615
        • Gansauge S.
        • Breitbart A.
        • Rinaldi N.
        • Schwarz-Eywill M.
        Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease).
        Ann Rheum Dis. 1997; 56: 382-385
        • Xiong W.
        • Lahita R.G.
        Pragmatic approaches to therapy for systemic lupus erythematosus.
        Nat Rev Rheumatol. 2014; 10: 97-107
        • Wada Y.
        • Kotani T.
        • Takeuchi T.
        • et al.
        Therapeutic drug monitoring of cyclosporine microemulsion in patients with corticosteroid-resistant systemic lupus erythematosus.
        Mod Rheumatol. 2015; 25: 708-713
        • Manger K.
        • Kalden J.R.
        • Manger B.
        Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study.
        Br J Rheumatol. 1996; 35: 669-675
        • Sheikholeslami M.
        • Hajialilo M.
        • Rasi Hashemi S.S.
        • Malek Mahdavi A.
        • Gojazadeh M.
        • Khabbazi A.
        Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis.
        Mod Rheumatol. 2018; 28: 523-529
        • Wetter D.A.
        • Davis M.D.
        Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.
        Mayo Clin Proc. 2009; 84: 979-984
        • Williams E.L.
        • Gadola S.
        • Edwards C.J.
        Anti-TNF-induced lupus.
        Rheumatology (Oxford). 2009; 48: 716-720
        • Soforo E.
        • Baumgartner M.
        • Francis L.
        • Allam F.
        • Phillips P.E.
        • Perl A.
        Induction of systemic lupus erythematosus with tumor necrosis factor blockers.
        J Rheumatol. 2010; 37: 204-205
        • Spillane A.P.
        • Xia Y.
        • Sniezek P.J.
        Drug-induced lupus erythematosus in a patient treated with adalumimab.
        J Am Acad Dermatol. 2007; 56: S114-S116
        • Shakoor N.
        • Michalska M.
        • Harris C.A.
        • Block J.A.
        Drug-induced systemic lupus erythematosus associated with etanercept therapy.
        Lancet. 2002; 359: 579-580
        • Jacob N.
        • Jacob C.O.
        On anti-tumor necrosis factor-induced systemic lupus erythematosus.
        J Rheumatol. 2010; 37: 3-5
        • Varada S.
        • Gottlieb A.B.
        • Merola J.F.
        • Saraiya A.R.
        • Tintle S.J.
        Treatment of coexistent psoriasis and lupus erythematosus.
        J Am Acad Dermatol. 2015; 72: 253-260
        • Schiff M.H.
        • Burmester G.R.
        • Kent J.D.
        • et al.
        Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.
        Ann Rheum Dis. 2006; 65: 889-894
        • De Bandt M.
        • Sibilia J.
        • Le Loet X.
        • et al.
        Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
        Arthritis Res Ther. 2005; 7: R545-R551
        • Winchester D.
        • Duffin K.C.
        • Hansen C.
        Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus.
        Lupus. 2012; 21: 1007-1010
        • De Souza A.
        • Strober B.E.
        • Merola J.F.
        • Oliver S.
        • Franks Jr., A.G.
        Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
        J Drugs Dermatol. 2012; 11: 1224-1226

      Linked Article